NATIONAL PUBLIC RADIO  by Poncie Rutsch                                                      March 25, 2015
From more than 900 miles away, Kpetermeni Siakor helped get volunteers to the right neighborhoods in his native Liberia during the height of the Ebola epidemic.

Kpetermeni Siakor (left), a Liberian who is studying in Ghana, used crowdsourcing software to help out during the Ebola epidemic. Courtesy of Ashesi University College

He did it with Ushahidi, crowdsourcing software that was developed in Kenya in 2008, when the country experienced a wave of post-election violence. The word Ushahidi means testimony in Swahili.

"The government had shut down internet connections and radio stations, so Ushahidi was born out of the need to let people know what is happening," says Siakor, 26. He's a computer science student at Ashesi University College in Accra, Ghana, and receives financial support from the MasterCard Foundation Scholars Program.

TIME MAGAZINE  by Alexandra Sifferlin                                             March 25, 2015
An efficacy trial for an Ebola vaccine launched in Guinea on Wednesday.

 A health worker prepares a vaccination on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus.

The vaccine, VSV-EBOV, was developed by the Public Health Agency of Canada and has already shown positive results in smaller safety trials. NewLink Genetics and Merck are collaborating on the vaccine, and the Guinean government and World Health Organization (WHO) are leading the trial, which is taking place in Basse-Guinée, a community where many Ebola cases spread.

A new study shows the durability of a novel 'disseminating' cytomegalovirus (CMV)-based Ebola virus (Zaire ebolavirus; EBOV) vaccine strategy that may eventually have the potential to reduce ebolavirus infection in wild African ape species.

These are western lowland gorillas, one of the great ape species threatened by Ebola. Credit: Copyright 2012 Chris Whittier

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

The multi-institutional study is led by Dr Michael Jarvis at Plymouth University, and is published today, 25th March 2015, in Vaccine.